文献速递浆细胞疾病

PVd方案用于来那度胺经治多发性骨髓瘤首次复发:OPTIMISMM研究亚组分析

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
PubMed 文献 · Leukemia · 2020-09-07

OPTIMISMM三期试验亚组分析纳入226例首次复发的多发性骨髓瘤患者,评估PVd对比Vd的疗效。结果显示,无论来那度胺难治状态、既往硼替佐米暴露或干细胞移植史,PVd均显著改善无进展生存期和总缓解率,未观察到新安全性信号。

要点

  • 首次复发患者中,PVd较Vd显著延长PFS,来那度胺难治者17.8 vs 9.5个月。
  • 来那度胺难治和敏感患者ORR均显著提高,分别85.9% vs 50.8%和95.7% vs 60.0%。
  • 既往硼替佐米暴露或干细胞移植史患者同样获益,无新安全性信号。

核心结论

  • PVd在首次复发多发性骨髓瘤患者中,包括来那度胺难治和既往常见一线治疗后,均显示优于Vd的疗效。

研究设计与样本

  • OPTIMISMM三期试验的亚组分析,纳入226例首次复发且既往来那度胺治疗的多发性骨髓瘤患者。

主要发现

  • 来那度胺难治患者PVd组中位PFS 17.8个月 vs Vd组9.5个月(P=0.0276)。
  • 来那度胺非难治患者PVd组中位PFS 22.0个月 vs Vd组12.0个月(P=0.0491)。
  • 既往硼替佐米暴露患者PVd组中位PFS 17.8个月 vs Vd组12.0个月(P=0.0068)。
  • 既往干细胞移植患者PVd组中位PFS 22.0个月 vs Vd组13.8个月(P=0.0241)。
  • 无既往硼替佐米暴露患者PVd组中位PFS 20.7个月 vs Vd组9.5个月(P=0.1055)。

关键数值与推荐

  • 来那度胺难治患者ORR:PVd组85.9% vs Vd组50.8%(P<0.001)。
  • 来那度胺非难治患者ORR:PVd组95.7% vs Vd组60.0%(P<0.001)。

临床怎么用

  • 首次复发多发性骨髓瘤患者,尤其来那度胺治疗后失败者,可考虑PVd方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analysis evaluated outcomes in patients at first relapse (N = 226) by lenalidomide-refractory status, prior bortezomib exposure, and prior stem cell transplant (SCT). Second-line PVd significantly improved PFS vs Vd in lenalidomide-refractory (17.8 vs 9.5 months; P = 0.0276) and lenalidomide-nonrefractory patients (22.0 vs 12.0 months; P = 0.0491), patients with prior bortezomib (17.8 vs 12.0 months; P = 0.0068), and patients with (22.0 vs 13.8 months; P = 0.0241) or without (16.5 vs 9.5 months; P = 0.0454) prior SCT. In patients without prior bortezomib, median PFS was 20.7 vs 9.5 months (P = 0.1055). Significant improvement in overall response rate was also observed with PVd vs Vd in lenalidomide-refractory (85.9% vs 50.8%; P < 0.001) and lenalidomide-nonrefractory (95.7% vs 60.0%; P < 0.001) patients, with similar results regardless of prior bortezomib or SCT. No new safety signals were observed. These data demonstrate the benefit of PVd at first relapse, including immediately after upfront lenalidomide treatment failure and other common first-line treatments.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Dimopoulos M, Weisel K, Moreau P, et al. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia. 2020. PMID: 32895455. doi:10.1038/s41375-020-01021-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。